Deals
Human Genome in Talks With Potential Suitors
This article is for subscribers only.
Human Genome Sciences Inc. said it’s in talks with “major” pharmaceutical and biotechnology companies about a potential transaction and adopted measures to avoid a hostile takeover by GlaxoSmithKline Plc.
Human Genome entered into confidentiality agreements with “certain parties” and is providing an opportunity to engage in due diligence reviews, the Rockville, Maryland-based company said today in a statement. Its board of directors unanimously said shareholders should reject Glaxo’s “inadequate” $2.6 billion offer.